Diaceutics stock analysis
Diaceutics (DIUXF) Stock Price & Analysis
DIUXF Stock Chart & Stats
- Day’s Range
- $2.47 - $2.74
- 52-Week Range
- $1.37 - $2.74
- Previous Close
- $2.57
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $220.90M
- Enterprise Value
- $117.62M
- Total Cash (Recent Filing)
- $8.10M
- Total Debt (Recent Filing)
- $2.09M
- Price to Earnings (P/E)
- ―
- Beta
- 0.11
- Next Earnings
- Mar 15, 2027 (Est.)
- EPS Estimate
- 0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Very low leverage gives Diaceutics financial flexibility to invest in its diagnostics intelligence platform and services without substantial debt pressure. A modest debt burden also improves resilience if growth slows, while sizable equity provides capacity to fund operations and strategic expansion.
Revenue Growth And Scale
Sustained revenue scaling indicates increasing demand for Diaceutics' diagnostics intelligence and precision-medicine services. Growth from a larger base can support operating leverage, strengthen customer relevance across pharma and biotech, and create a broader foundation for future recurring platform revenue.
Return To Positive Free Cash Flow
Positive operating and free cash flow represent a meaningful improvement in the company's ability to fund itself internally. If maintained, better cash generation can reduce dependence on external capital, support platform investment, and provide greater flexibility as precision-medicine demand develops.
Bears Say
Operating Profitability Remains Unproven
Despite revenue growth and a small net profit, continued operating losses show that the core business has not yet established durable operating profitability. Margin volatility may limit reinvestment capacity and makes it harder to assess whether future growth will translate consistently into stronger earnings.
Very Low Return On Equity
Minimal returns on the equity base indicate that Diaceutics has not consistently converted invested capital into meaningful earnings. This weak capital productivity can constrain long-term compounding and suggests that improvements in revenue and net income have not yet produced a durable economic return.
Uneven Historical Cash Conversion
The 2025 cash-flow rebound is encouraging, but prior large outflows and low operating cash generation point to inconsistent cash conversion and spending discipline. Such variability can make internal funding less dependable and may complicate investment planning through the next several quarters.
Diaceutics News
DIUXF FAQ
What was Diaceutics’s price range in the past 12 months?
What is Diaceutics’s market cap?
When is Diaceutics’s upcoming earnings report date?
How were Diaceutics’s earnings last quarter?
Is Diaceutics overvalued?
Does Diaceutics pay dividends?
What is Diaceutics’s EPS estimate?
How many shares outstanding does Diaceutics have?
What happened to Diaceutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Diaceutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Diaceutics
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This platform features DXRX data solutions, providing access to extensive diagnostic testing data pipelines from a broad network of laboratories, including real-time DXRX signal alerts, lab and physician mapping, and a testing dashboard. The DXRX platform also hosts a marketplace where laboratories, pharmaceutical firms, and diagnostic companies can connect to collaborate on precision medicine diagnostics. Diaceutics further provides DXRX Patient Journey, a tool for pharmaceutical clients to conduct detailed longitudinal analyses of individual patient biomarker testing paths, helping identify opportunities for earlier intervention and treatment. DXRX Lab Benchmarking allows laboratories to sharpen their competitive edge by comparing their key criteria against industry counterparts, encompassing metrics such as disease focus, testing methodologies, market share, turnaround times, and their standing as leaders in specific diagnostic fields. The DXRX Test Reimbursement service assists pharma clients in funding novel companion diagnostics, thereby shortening the time required for their widespread adoption. Furthermore, DXRX Test Signal delivers immediate notifications of testing events, empowering pharmaceutical clients to swiftly identify therapeutically actionable patients. Beyond the platform, Diaceutics furnishes services for diagnostic landscape analysis, strategic planning, implementation, and ongoing tracking, alongside expert consulting tailored to precision medicine diagnostics. Its extensive service portfolio also covers test standardization, quality evaluations, optimization of test reports, technical laboratory support, assistance with test access and reimbursement, laboratory training, and various educational resources.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Ryan Keeling
- Employees
- 205
- Website
- www.diaceutics.com
- Address
- Building Two, Belfast, AT, BT9 6GW, GB
Diaceutics (DIUXF) Earnings & Revenues
DIUXF Earnings Call
Earnings Call SentimentPositive
The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.
View all DIUXF earnings summariesDIUXF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 3 |
| Technical Analysis | 3 | 3 | 3 |
| Moving Averages | 12 | 0 | 0 |












